Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized double-blind placebo-controlled study of oral CFTX-1554 in healthy volunteers
NL-OMON51471Phase 1Completed
- Sponsor
- Confo Therapeutics
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CFTX-1554 in Peripheral neuropathic pain, sponsored by Confo Therapeutics. Primary endpoint: Safety and tolerability. Started Feb 2022; status: completed.
02
Drugs
CFTX-1554
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NL-OMON51471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51471.